Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL

Blood (2024) 144 (Supplement 1): 636.

https://doi.org/10.1182/blood-2024-205421

Published: 2024

Journal Articles

Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

Steffen Krohn, Carina Lynn Gehlert, Dorothee Winterberg, Alexander Jochimsen, Ammelie Svea Boje, Natalie Baum, Claudia D Baldus, Monika Brüggemann, Gunnar Cario, Martin Schrappe, Lennart Lenk, Martin Gramatzki, Katja Klausz, Christian Kellner, Matthias Peipp

Blood (2024) 144 (Supplement 1): 4173.

https://doi.org/10.1182/blood-2024-207737

Published: 2024

Journal Articles

A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies

Blood (2024) 144 (Supplement 1): 914.

https://doi.org/10.1182/blood-2024-210243

Published: 2024

Journal Articles

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

Blood (2024) 143 (26): 2735–2748.

https://doi.org/10.1182/blood.2023021088

Published: 2024

Includes: Supplemental data

Journal Articles

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4190.

https://doi.org/10.1182/blood-2023-185875

Published: 2023

Journal Articles

The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

Lennart Lenk, Irène Baccelli, Dorothee Winterberg, Anna Dietterle, Frédérique Corallo, Julien Taurelle, Emma Narbeburu, Anna Laqua, Beat Bornhauser, Jean-Pierre Bourquin, Fotini Vogiatzi, Martin Schrappe, Gunnar Cario, Monika Brüggemann, Nicolas Poirier, Denis Martin Schewe

Blood (2022) 140 (Supplement 1): 1045–1047.

https://doi.org/10.1182/blood-2022-162261

Published: 2022

Journal Articles

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

Blood (2022) 140 (1): 45–57.

https://doi.org/10.1182/blood.2021014485

Published: 2022

Includes: Supplemental data

Journal Articles

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B Cell Precursor Acute Lymphoblastic Leukemia

Lennart Lenk, Dorothee Winterberg, Fotini Vogiatzi, Anna Laqua, Lea Spory, Ahmad Mayar, Christian Vokuhl, Julia Richter, Michela Carlet, Irmela Jeremias, Thomas Valerius, Martin Schrappe, Gunnar Cario, Hassan Jumaa, Elias Hobeika, Monika Brüggemann, Ameera Alsadeq, Denis Martin Schewe

Blood (2021) 138 (Supplement 1): 2388.

https://doi.org/10.1182/blood-2021-148429

Published: 2021

Journal Articles

IL7R Targeting Using OSE-127 Shows Robust Anti-Leukemic Activity in B-Cell Precursor Acute Lymphoblastic Leukemia Xenografts

Lennart Lenk, Irène Baccelli, Dorothee Winterberg, Frédérique Corallo, Fotini Vogiatzi, Lea Spory, Martin Schrappe, Gunnar Cario, Anna Laqua, Monika Brüggemann, Nicolas Poirier, Denis Martin Schewe

Blood (2021) 138 (Supplement 1): 1313.

https://doi.org/10.1182/blood-2021-150323

Published: 2021

Journal Articles

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Fotini Vogiatzi, PhD, Kristina Müller, Dorothee Winterberg, Thies Rösner, PhD, Lennart Lenk, PhD, Gunnar Cario, MD PhD, Martin Schrappe, MDPhD, Andreas E. Kulozik, MD PhD, Beat Bornhauser, Jean-Pierre Bourquin, MD PhD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140270

Published: 2020

Journal Articles

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Fotini Vogiatzi, Dorothee Winterberg, Lennart Lenk, Swantje Buchmann, Gunnar Cario, Martin Schrappe, Matthias Peipp, Paulina Richter-Pechanska, Andreas E. Kulozik, Jana Lentes, Anke K. Bergmann, Thomas Valerius, Fabian-Simon Frielitz, Christian Kellner, Denis M. Schewe

Blood (2019) 134 (8): 713–716.

https://doi.org/10.1182/blood.2019000904

Published: 2019

Includes: Supplemental data

NARROW

CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL

Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

A Novel Platform Technology for the Development of NK Cell-Based Cellular Immunotherapies

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B Cell Precursor Acute Lymphoblastic Leukemia

IL7R Targeting Using OSE-127 Shows Robust Anti-Leukemic Activity in B-Cell Precursor Acute Lymphoblastic Leukemia Xenografts

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only